Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Assets: 2019-2025

Historic Non-Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $382.5 million.

  • IDEAYA Biosciences' Non-Current Assets rose 24.32% to $382.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.5 million, marking a year-over-year increase of 24.32%. This contributed to the annual value of $434.4 million for FY2024, which is 272.27% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Non-Current Assets stood at $382.5 million, which was up 7.54% from $355.7 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Non-Current Assets ranged from a high of $434.4 million in Q4 2024 and a low of $17.5 million during Q3 2022.
  • Its 3-year average for Non-Current Assets is $236.3 million, with a median of $260.5 million in 2024.
  • As far as peak fluctuations go, IDEAYA Biosciences' Non-Current Assets spiked by 1,248.83% in 2021, and later slumped by 86.61% in 2022.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Non-Current Assets stood at $130.4 million in 2021, then plummeted by 86.56% to $17.5 million in 2022, then soared by 566.19% to $116.7 million in 2023, then skyrocketed by 272.27% to $434.4 million in 2024, then climbed by 24.32% to $382.5 million in 2025.
  • Its Non-Current Assets stands at $382.5 million for Q3 2025, versus $355.7 million for Q2 2025 and $392.8 million for Q1 2025.